Moderna, Inc. (NASDAQ:MRNA)

PRESS RELEASE

published on 03/26/2024 at 12:00, 7 months 27 days ago

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Moderna's mRNA-1283 shows higher immune response than mRNA-1273.222 in Phase 3 trial. Next-generation vaccine offers longer shelf life and storage benefits, paving way for flu-COVID combo vaccine, mRNA-1083

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 MRNA-1273.222
BRIEF

published on 02/29/2024 at 13:00, 8 months 22 days ago

Moderna Announces Fifth Annual Vaccine-Focused Investor Event

Investors Webcast Moderna Investor Event MRNA Vaccines
PRESS RELEASE

published on 02/29/2024 at 13:00, 8 months 22 days ago

Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
Moderna, Inc. announces its fifth annual Investor Event focusing on vaccines and business updates on March 27, 2024. Presentation at 9:00 a.m. ET. Live webcast available on the Moderna website

Webcast MRNA Medicine Moderna Investor Event MRNA Vaccines
BRIEF

published on 02/28/2024 at 13:00, 8 months 23 days ago

Moderna announces participation in investor conferences

Investor Conferences Webcast MRNA Technology Moderna Health
PRESS RELEASE

published on 02/28/2024 at 13:00, 8 months 23 days ago

Moderna to Present at Upcoming Investor Conferences in March 2024
Moderna, Inc. to participate in upcoming investor conferences and showcase advancements in mRNA technology. Visit investors.modernatx.com for webcast details

Investor Conferences Healthcare Moderna Inc. MRNA Technology COVID-19 Vaccines
BRIEF

published on 02/22/2024 at 12:30, 9 months ago

Moderna announces mixed financial results for 2023 and optimistic outlook for 2024

2023 Financial Results 2024 Forecasts Moderna RSV Vaccine Research Pipeline
PRESS RELEASE

published on 02/22/2024 at 12:30, 9 months ago

Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Moderna, Inc. reports Q4 revenues of $2.8 billion with a GAAP net income of $217 million. Expects regulatory approvals for RSV vaccine and forecasts 2024 product sales of $4 billion

Financial Results Moderna Inc. RSV Vaccine Product Sales Regulatory Approvals
PRESS RELEASE

published on 02/07/2024 at 06:00, 9 months 15 days ago

Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
Moderna, Inc.'s CEO Stéphane Bancel elected to National Academy of Engineering for distinguished contributions to engineering and manufacturing of pharmaceutical products, including COVID-19 vaccine. Company has 45 mRNA therapeutic and vaccine programs in pipeline

Moderna Inc COVID-19 Vaccine Stéphane Bancel National Academy Of Engineering MRNA Technology
PRESS RELEASE

published on 02/01/2024 at 13:00, 9 months 21 days ago

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Moderna, Inc. to report Q4 and full year 2023 financial results and provide corporate update in live conference call and webcast on February 22, 2024. Archived webcast available for one year

Financial Results Conference Call Moderna Inc Webcast MRNA Medicine
PRESS RELEASE

published on 01/31/2024 at 23:45, 9 months 21 days ago

Moderna Named to Fortune's List of World's Most Admired Companies
Moderna, Inc. has been recognized on Fortune's World's Most Admired Companies list, positioning among the top-50 companies. The company focuses on mRNA medicine for disease prevention and treatment, recognized for innovation and public health impact

Moderna Inc. Fortune Most Admired Companies MRNA Medicine Corporate Reputation

Published on 11/22/2024 at 18:45, 2 hours 4 minutes ago

CORRECTING and REPLACING the Not-So-Secret Lives of REAL "Mormon" Wives - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/22/2024 at 16:00, 4 hours 49 minutes ago

Manimal Tales Unveils Two New Personalized Christmas-Themed Books to Spread Holiday Magic and Joy!
Published on 11/22/2024 at 15:55, 4 hours 54 minutes ago

Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Published on 11/22/2024 at 15:15, 5 hours 34 minutes ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Published on 11/22/2024 at 14:45, 6 hours 4 minutes ago

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 2 hours 35 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 2 hours 49 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 2 hours 56 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 3 hours 54 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 4 hours 49 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 6 hours 14 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 1 day 13 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 1 hour ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 3 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 3 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News